Reuter U, et al. Long-term efficacy and safety of erenumab: Results from 64 weeks of the LIBERTY study. IHC-OR-006. IHC 2019 5-8 sept. Dublin, Ierland.
Op weg naar precisie
jan 2019 | Multipele Sclerose
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen